Chief Medical Officer
Rallybio
Steve Ryder is a senior pharmaceutical R&D executive with broad experience at the highest levels of global development leadership. During the past 35+ years, he has been centrally involved in the global development of many products. In January 2019 he joined the team at Rallybio, a biotechnology company dedicated to transforming the lives of patients with devastating rare and ultra-rare disease. Prior to this he was SVP, Chief Development Officer at Alexion Pharmaceuticals (2013- 2018) where responsibilities included the global development, registration, and approval of new biological/drug candidates and building the organization that sustains these activities, and founding President, Astellas Pharma Global Development (2008-2013) leading an organization of over 1000 staff in Japan (Tokyo), the US (Northbrook IL), and the EU ((Leiden, Netherlands) and reporting directly to the global CEO of Astellas Pharma, Inc. Recent approvals include Ultomiris™ for patients with Paroxysmal Nocturnal Hemoglobinuria (US ’18), Soliris™ for patients with refractory generalized Myasthenia Gravis (EU/US/Japan ’17), Strensiq™ for the ultra-rare disease of hypophosphatasia (Japan/US/EU ’15), and Betanis/Myrbetriq™ for OAB (Japan ‘11, US/EU ‘12), the first beta-3 agonist approved for any indication. He is a member of the Board of Directors of Levo Therapeutics. He is past-President of the American Society of Clinical Pharmacology and Therapeutics, has held leadership positions in the Health Section Governing Board, Regulatory Executive Committee, and Board of BIO and the Science and Regulatory section of PhRMA, is a member of the Clinical Pharmacology Advisory Board of the PhRMA Foundation and several editorial boards. He has served as the industry representative on FDA’s Metabolic/Endocrine Drugs Advisory Committee and is past-Chairman of the Board of Directors of Gaylord Hospital (Wallingford, CT).
Disclosure information not submitted.
Thursday, January 13, 2022
9:00 PM – 10:00 PM ET
Friday, January 14, 2022
11:15 AM – 12:15 PM ET
.png)